Risk of Recurrence by Nodal Status and High-Risk Features in Patients with HR+, HER2-, Early Breast Cancer: An Analysis of Real-world Data

被引：0
|
作者：
Grimes, B. [1 ]
Tolaney, S. M. [2 ]
Sammons, S. [2 ]
Cortes, J. [3 ,4 ]
Liepa, A. M. [1 ]
Sugihara, T. [5 ]
Cui, Z. Lin [1 ]
Gathirua-Mwangi, W. [1 ]
Shahir, A. [1 ]
Monaco, M. [1 ]
Neven, P. [6 ]
Johnston, S. [7 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN USA
[2] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[3] Quironsalud Grp, Inst Int Breast Canc Ctr, Dept Med, Pangaea Oncol, Barcelona, Spain
[4] Univ Europea Madrid, Fac Biomed & Hlth Sci, Madrid, Spain
[5] Syneos Hlth, Morrisville, NC USA
[6] Univ Hosp Leuven, Louvain, Belgium
[7] Royal Marsden NHS Fdn Trust, London, England
来源：
BREAST | 2025年 / 80卷
关键词：
D O I：
10.1016/j.breast.2025.103897
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P003
引用
收藏
页数：2
相关论文
共 50 条
  • [41] REAL-WORLD DATA: IMPACT OF LOW HER-2 EXPRESSION IN METASTATIC HR+/HER2-BREAST CANCER TREATED WITH PALBOCICLIB
    Montenegro, Maria Alexandra
    Simao, Diana Cardoso
    Mendes, Jose Leao
    Fernandes, Leonor Raposo
    Martins, Maria Manuela
    Da Luz, Ricardo
    Oliveira, Sonia Duarte
    BREAST, 2023, 71 : S57 - S58
  • [42] Abemaciclib for treating patients with HR+, HER2-advanced/metastatic breast cancer in Spain: a real-world study
    Blancas, I.
    Fakhouri, W.
    Molero, A.
    Diaz-Cerezo, S.
    Haro, J. M.
    Faris, L. H.
    Sanchez-Bayona, R.
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : S59 - S60
  • [43] The Role of Ki-67 in HR+/HER2-Breast Cancer: A Real-World Study of 956 Patients
    Ma, Qin
    Liu, Yao-Bang
    She, Tong
    Liu, Xin-Lan
    BREAST CANCER-TARGETS AND THERAPY, 2024, 16 : 117 - 126
  • [44] Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
    Hamilton, Erika P.
    Kim, Jee Hyun
    Eigeliene, Natalja
    Mavroudis, Dimitrios
    Median, Dragos Mircea
    Marconato, Heloisa
    Shevnia, Serhii
    Ozyilkan, Ozgur
    Puig, Juan Manuel
    Shannon, Catherine M.
    Munoz, Maria
    San Antonio, Belen
    Wei, Ran
    O'Shaughnessy, Joyce
    Johnston, Stephen R. D.
    Guarneri, Valentina
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2-early breast cancer in China
    Wei, Qiran
    Xu, Yuting
    Liu, Wei
    Guan, Xin
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [46] Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2–early breast cancer in China
    Qiran Wei
    YuTing Xu
    Wei Liu
    Xin Guan
    Cost Effectiveness and Resource Allocation, 21
  • [47] Female breast cancers (T1-2, N0, M0, HR+, HER2-) with an intermediate genetic-based recurrence risk: a real-world estimate in Italy
    Crocetti, Emanuele
    Ravaioli, Alessandra
    Amadori, Dino
    Mancini, Silvia
    Vattiato, Rosa
    Giuliani, Orietta
    Baldacchini, Flavia
    Falcini, Fabio
    TUMORI JOURNAL, 2019, 105 (06): : 483 - 487
  • [48] Correlation analysis of invasive disease-free survival and overall survival in a real-world population of patients with HR+/HER2-early breast cancer
    Graff, Stephanie L.
    Tolaney, Sara M.
    Hart, Lowell L.
    Razavi, Pedram
    Janni, Wolfgang
    Schwartzberg, Lee S.
    Danyliv, Andriy
    Akdere, Murat
    Ferrusi, Ilia
    Adhikary, Rishi Rajat
    O'Shaughnessy, Joyce A.
    CANCER, 2025, 131 (07)
  • [49] Patient profiles, management and treatment patterns in HR+, HER2-early breast cancer in a real-world setting in Spain
    Martin, Miguel
    Saenz, Jose Angel Garcia
    Blancas, Isabel
    Molero, Alberto
    Atienza, Manuel
    Cervera, Jose Manuel
    Brown, Jacqueline
    Rider, Alex
    Williams, Rhys
    Alba, Emilio
    CANCER RESEARCH, 2022, 82 (04)
  • [50] Breast cancer specific quality of life in HR+/HER2-advanced/metastatic breast cancer patients in a real-world setting.
    Wood, Robert
    Mitra, Debanjali
    De Courcy, Jonathan
    Iyer, Shrividya
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345